E2F3 is altered in 1.06% of all cancers with bladder urothelial carcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and colon adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in E2F3 are E2F3 Amplification (0.48%), E2F3 Loss (0.03%), E2F3 R134* (0.01%), E2F3 V25A (0.01%), and E2F3 F44L (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.